Atypical Lipomatous Tumor
Atypical lipomatous tumor (ALT) is an intermediate, locally aggressive fatty tumor. In the World Health Organization (WHO) classification, ALT and well-differentiated liposarcoma (WDLPS) share the same biology, histology and molecular abnormalities. The term "atypical lipomatous tumor" is preferred for lesions in superficial soft tissue or the limbs, where wide excision can remove the tumor completely and there is no risk of distant metastasis (tumor-related mortality is close to 0%).
At the molecular level, ALT is defined by amplification of the MDM2 and CDK4 genes on chromosome 12q13–15, seen as ring or giant marker chromosomes. Under the microscope it shows fat cells of varying size, atypical hyperchromatic stromal cells and fibrous septa. As a result, ALT is easily mistaken for a large ordinary lipoma (giant lipoma), leading to inadequate margins (R1/R2) and local recurrence, or overcalled as high-grade liposarcoma, leading to unnecessary amputation or destructive surgery.
At Haute-Derma, we follow a standardized molecular diagnostic pathway: confirming MDM2/CDK4 amplification by immunohistochemistry (IHC) and FISH, mapping the lesion with 3.0T MRI, and performing microsurgical wide excision that preserves as much function and appearance as possible.
Clinical Features and Pathologic Classification
Pathogenesis and Molecular Genetics
- Amplification of the 12q13–15 Locus (MDM2/CDK4):
- The hallmark alteration in ALT/WDLPS is amplification of the 12q13–15 region, which carries the key oncogenes MDM2 (a protein that inhibits the tumor suppressor p53) and CDK4 (a protein that drives the cell cycle).
- Demonstrating MDM2 amplification by FISH, or strong MDM2/CDK4 staining on immunohistochemistry, is the gold standard for telling ALT apart from a benign lipoma.
- Epidemiology and Typical Locations:
- Most common in middle-aged and older adults (40–70 years); men and women are affected about equally.
- Favored sites: deep soft tissue of the limbs (especially the thigh, which accounts for more than 60% of cases), the buttock, the shoulder girdle and the spermatic cord. The tumor grows quietly to a large size (>5–10 cm) and is painless or causes only mild pressure symptoms.
Histopathology (the Gold Standard)
Microscopically, ALT loses the uniform appearance of normal fat. The key features are:
- Variation in Fat Cell Size (Adipocytic Anisocytosis): Unlike a benign lipoma, whose fat cells are uniform, ALT contains mature adipocytes that range markedly in size, from very small to very large.
- Atypical Hyperchromatic Stromal Cells: Within the fibrous septa that run through the fat lie stromal cells with large, irregular, darkly staining (hyperchromatic) and pleomorphic nuclei.
- Atypical Lipoblasts: Scattered cells contain several small fat vacuoles that indent a central hyperchromatic nucleus, giving it a scalloped outline.
Differential Diagnosis and Immunohistochemistry (IHC)
Microscopic and molecular differences between these entities are decisive for treatment planning:
| Condition | IHC Markers and Genetics | Distinguishing Microscopic Features |
|---|---|---|
| Atypical lipomatous tumor (ALT) | MDM2 (+), strong nuclear; CDK4 (+); p16 (+); MDM2 amplification (+) on FISH | Fat cells of uneven size; hyperchromatic stromal cells in fibrous septa; atypical lipoblasts. |
| Giant lipoma | MDM2 (-); CDK4 (-); p16 (- or weak) | Uniform, fully mature fat cells; thin septa without atypical cells. |
| Dedifferentiated liposarcoma (DDLPS) | MDM2 (+); CDK4 (+); high Ki-67 proliferation index (>20–30%) | ALT component transforming into non-fatty high-grade sarcoma; numerous atypical mitoses; necrosis. |
| Spindle cell lipoma (SCL) | CD34 (+); loss of Rb (Rb -); MDM2 (-); CDK4 (-) | Uniform spindle cells; ropey collagen bundles; loss of Rb protein expression. |
Our Approach to Treating Atypical Lipomatous Tumor
Haute-Derma manages ALT on three principles: precise molecular diagnosis, function-sparing wide excision with clear (R0) margins, and regular clinical follow-up:
- Confirming the Diagnosis With MDM2/CDK4 IHC and FISH: Ruling out an ordinary benign lipoma with 100% certainty before surgery lets the surgeon plan a resection with a safe (R0) margin, rather than a simple "shell-out" that can leave atypical cells behind.
- Function-Sparing Microsurgical Wide Resection: The tumor is removed with a safe rim of healthy tissue (usually including the overlying muscle fascia), while the main nerve bundles, large blood vessels and motor tendons of the limb are fully preserved.
- Tissue Reconstruction and Surface Cosmesis: Local rotation flaps or multilayer microsurgical closure fill the deep tissue defect, minimizing skin depression and unsightly scarring.
How We Diagnose Atypical Lipomatous Tumor at Haute-Derma
- Clinical Examination and Limb Assessment: We examine large masses lying deep within muscle or beneath the fascia of the thigh, buttock or shoulder, assessing their consistency, attachment to the fascia and any signs of nerve or vessel compression.
- Advanced Imaging With High-Resolution 3.0T MRI: MRI is the best imaging test for ALT. The tumor is mostly fat signal (high on T1W/T2W) but characteristically contains thick septa (>2 mm) and nodular or patchy non-fatty areas that enhance mildly to moderately with contrast.
- Core Needle Biopsy and Molecular Testing: Several tissue cores are taken from areas that look suspicious on MRI (especially thick septa), followed by H&E staining, an IHC panel of MDM2, CDK4 and p16, and FISH to confirm MDM2 amplification.
Specialized Treatment Options at Haute-Derma
- Wide Local Excision (the Gold Standard):
- Indication: Required for every biopsy-confirmed ALT.
- Technique: Through a long incision along the axis of the limb or muscle, the surgeon removes the tumor intact with its surrounding fascia and a safe margin of healthy tissue (>1 cm, or including the natural muscle fascia). Feeding vessels are thoroughly clamped and cauterized with microsurgical instruments.
- Margin Assessment of the Specimen (R0): The resected specimen is inked and fully sectioned to confirm that no tumor cells (MDM2-positive) remain at the cut edge (R0).
- Scheduled Follow-Up for Local Recurrence: Patients are enrolled in clinical follow-up with MRI every 6 months for the first 2 years, then yearly up to 5 years, so any local recurrence is caught early.
